The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
One mouse, one patient paradigm: New avatars of personalized cancer therapy
Open accessAbstract
Over the last few decades, study of cancer in mouse models has gained popularity. Sophisticated genetic manipulation technologies and commercialization of these murine systems have made it possible to generate mice to study human disease. Given the large socio-economic burden of cancer, both on academic research and the health care industry, there is a need for in vivo animal cancer models that can provide a rationale that is translatable to the clinic. Such a bench-to-bedside transition will facilitate a long term robust strategy that is economically feasible and clinically effective to manage cancer. The major hurdles in considering mouse models as a translational platform are the lack of tumor heterogeneity and genetic diversity, which are a hallmark of human cancers. The present review, while critical of these pitfalls, discusses two newly emerging concepts of personalized mouse models called “Mouse Avatars” and Co-clinical Trials. Development of “Mouse Avatars” entails implantation of patient tumor samples in mice for subsequent use in drug efficacy studies. These avatars allow for each patient to have their own tumor growing in an in vivo system, thereby allowing the identification of a personalized therapeutic regimen, eliminating the cost and toxicity associated with non-targeted chemotherapeutic measures. In Co-clinical Trials, genetically engineered mouse models (GEMMs) are used to guide therapy in an ongoing human patient trial. Murine and patient trials are conducted concurrently, and information obtained from the murine system is applied towards future clinical management of the patient’s tumor. The concurrent trials allow for a real-time integration of the murine and human tumor data. In combination with several molecular profiling techniques, the “Mouse Avatar” and Co-clinical Trial concepts have the potential to revolutionize the drug development and health care process. The present review outlines the current status, challenges and the future potential of these two new in vivo approaches in the field of personalized oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Phenotypic characterization of human colorectal cancer stem cells
Dalerba, P., Dylla, S. J., Park, I.-K., Liu, R., Wang, X., Cho, R. W., Hoey, T., Gurney, A., Huang, E. H., Simeone, D. M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703478104 · Cited by 2,184
Patient-derived tumour xenografts as models for oncology drug development
Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M., Arcaroli, J. J., Messersmith, W. A., & Eckhardt, S. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.61 · Cited by 1,277
Characterizing the cancer genome in lung adenocarcinoma
Weir, B. A., Woo, M. S., Getz, G., Perner, S., Ding, L., Beroukhim, R., Lin, W. M., Province, M. A., Kraja, A., Johnson, L. A., et al. (2007) · Nature · doi:10.1038/nature06358 · Cited by 1,105
Von Hoff, D. D., Ramanathan, R. K., Borad, M. J., Laheru, D. A., Smith, L. S., Wood, T. E., Korn, R. L., Desai, N., Trieu, V., Iglesias, J. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.5742 · Cited by 1,044
Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939 · cited 2×
“Identification of Her2 amplification as a genetic lesion in cetuximab-resistant colorectal tumors [52]”
BackgroundReconstruction of functionally normal and malignant human breast tissues in mice
Kuperwasser, C., Chavarria, T., Wu, M., Magrane, G., Gray, J. W., Carey, L., Richardson, A., & Weinberg, R. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401064101 · Cited by 804
DNA Topoisomerase I—Targeted Chemotherapy of Human Colon Cancer in Xenografts
Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R., & Potmesil, M. (1989) · Science · doi:10.1126/science.2555920 · Cited by 650
Mascaux, C., Iannino, N., Martin, B., Paesmans, M., Berghmans, T., Dusart, M., Haller, A., Lothaire, P., Meert, A.-P., Noel, S., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602258 · Cited by 605
He, L.-Z., Guidez, F., Tribioli, C., Peruzzi, D., Ruthardt, M., Zelent, A., & Pandolfi, P. P. (1998) · Nature Genetics · doi:10.1038/ng0298-126 · Cited by 557
High drug attrition rates—where are we going wrong?
Hutchinson, L., & Kirk, R. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.34 · Cited by 517
Economic Burden of Cancer in the United States: Estimates, Projections, and Future Research
Yabroff, K. R., Lund, J., Kepka, D., & Mariotto, A. (2011) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0650 · Cited by 503
Warrell, R. P., He, L.-Z., Richon, V., Calleja, E., & Pandolfi, P. P. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.21.1621 · Cited by 502
Douillard, J.-Y., Shepherd, F. A., Hirsh, V., Mok, T., Socinski, M. A., Gervais, R., Liao, M.-L., Bischoff, H., Reck, M., Sellers, M. V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.3030 · Cited by 492
Establishment of human tumor xenografts in immunodeficient mice
Morton, C. L., & Houghton, P. J. (2007) · Nature Protocols · doi:10.1038/nprot.2007.25 · Cited by 489
Mouse xenograft models vs GEM models for human cancer therapeutics
Richmond, A., & Su, Y. (2008) · Disease Models & Mechanisms · doi:10.1242/dmm.000976 · Cited by 467
Daniel, V. C., Marchionni, L., Hierman, J. S., Rhodes, J. T., Devereux, W. L., Rudin, C. M., Yung, R., Parmigiani, G., Dorsch, M., Peacock, C. D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4210 · Cited by 467
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Chen, Z., Cheng, K., Walton, Z., Wang, Y., Ebi, H., Shimamura, T., Liu, Y., Tupper, T., Ouyang, J., Li, J., et al. (2012) · Nature · doi:10.1038/nature10937 · Cited by 446 · cited 10×
“Concordance between the engrafted murine tumors and the original patient tumors have been established in several cancer models such as non-small cell lung cancer (NSCLC), small cell lung cancer and pancreatic tumors amongst others [11–13].”
BackgroundMethodInfluentialA PMLRAR α transgene initiates murine acute promyelocytic leukemia
Brown, D., Kogan, S., Lagasse, E., Weissman, I., Alcalay, M., Pelicci, P. G., Atwater, S., & Bishop, J. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2551 · Cited by 434
Steels, E., Paesmans, M., Berghmans, T., Branle, F., Lemaitre, F., Mascaux, C., Meert, A. P., Vallot, F., Lafitte, J. J., & Sculier, J. P. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.00062201 · Cited by 418
An In vivo Platform for Translational Drug Development in Pancreatic Cancer
Rubio-Viqueira, B., Jimeno, A., Cusatis, G., Zhang, X., Iacobuzio-Donahue, C., Karikari, C., Shi, C., Danenberg, K., Danenberg, P. V., Kuramochi, H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0113 · Cited by 414
Cheon, D.-J., & Orsulic, S. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.3.121806.154244 · Cited by 395
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas
Chakravarti, A., Zhai, G., Suzuki, Y., Sarkesh, S., Black, P. M., Muzikansky, A., & Loeffler, J. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.193 · Cited by 377
(2018) · Cancer Genomics & Proteomics · doi:10.21873/cgp · Cited by 372
Julien, S., Merino-Trigo, A., Lacroix, L., Pocard, M., Goéré, D., Mariani, P., Landron, S., Bigot, L., Nemati, F., Dartigues, P., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0372 · Cited by 360
Grisolano, J. L., Wesselschmidt, R. L., Pelicci, P. G., & Ley, T. J. (1997) · Blood · doi:10.1182/blood.v89.2.376 · Cited by 352
Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer
Chang, K.-H., Li, R., Papari-Zareei, M., Watumull, L., Zhao, Y. D., Auchus, R. J., & Sharifi, N. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107898108 · Cited by 346
Shao, W., Fanelli, M., Ferrara, F. F., Riccioni, R., Rosenauer, A., Davison, K., Lamph, W. W., Waxman, S., Pelicci, P. G., Lo Coco, F., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.2.124 · Cited by 344
Acute leukemia with promyelocytic features in PML/RARα transgenic mice
He, L.-Z., Tribioli, C., Rivi, R., Peruzzi, D., Pelicci, P. G., Soares, V., Cattoretti, G., & Pandolfi, P. P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5302 · Cited by 339
Lallemand-Breitenbach, V., Guillemin, M.-C., Janin, A., Daniel, M.-T., Degos, L., Kogan, S. C., Michael Bishop, J., & de Thé, H. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.7.1043 · Cited by 305
Pandolfi, P. P., Grignani, F., Alcalay, M., Mencarelli, A., Biondi, A., Lo‐Coco, F., Grignani, F., & Pelicci, P. G. (1991) · PubMed · Cited by 305
He, L.-Z., Tolentino, T., Grayson, P., Zhong, S., Warrell, R. P., Rifkind, R. A., Marks, P. A., Richon, V. M., & Pandolfi, P. P. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11537 · Cited by 303
Fichtner, I., Rolff, J., Soong, R., Hoffmann, J., Hammer, S., Sommer, A., Becker, M., & Merk, J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0138 · Cited by 286
Prevalence and specificity of LKB1 genetic alterations in lung cancers
Matsumoto, S., Iwakawa, R., Takahashi, K., Kohno, T., Nakanishi, Y., Matsuno, Y., Suzuki, K., Nakamoto, M., Shimizu, E., Minna, J. D., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210418 · Cited by 280
Villarroel, M. C., Rajeshkumar, N. V., Garrido-Laguna, I., De Jesus-Acosta, A., Jones, S., Maitra, A., Hruban, R. H., Eshleman, J. R., Klein, A., Laheru, D., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0893 · Cited by 249
Garrido-Laguna, I., Uson, M., Rajeshkumar, N. V., Tan, A. C., de Oliveira, E., Karikari, C., Villaroel, M. C., Salomon, A., Taylor, G., Sharma, R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0341 · Cited by 247
Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review
Jin, K., Teng, L., Shen, Y., He, K., Xu, Z., & Li, G. (2010) · Clinical and Translational Oncology · doi:10.1007/s12094-010-0540-6 · Cited by 217
Genetically Engineered Mouse Models in Cancer Research
(2010) · Advances in Cancer Research · doi:10.1016/s0065-230x(10)06004-5 · Cited by 206
Rego, E. M., He, L.-Z., Warrell, R. P., Wang, Z.-G., & Pandolfi, P. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180290497 · Cited by 194
Restoring invisible and abandoned trials: a call for people to publish the findings
Doshi, P., Dickersin, K., Healy, D., Vedula, S. S., & Jefferson, T. (2013) · BMJ · doi:10.1136/bmj.f2865 · Cited by 190
Translational research: 4 ways to fix the clinical trial
Ledford, H. (2011) · Nature · doi:10.1038/477526a · Cited by 187
John, T., Kohler, D., Pintilie, M., Yanagawa, N., Pham, N.-A., Li, M., Panchal, D., Hui, F., Meng, F., Shepherd, F. A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2224 · Cited by 176
The Promise of Patient-Derived Xenografts: The Best Laid Plans of Mice and Men
Kopetz, S., Lemos, R., & Powis, G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2408 · Cited by 176
Hammers, H. J., Verheul, H. M., Salumbides, B., Sharma, R., Rudek, M., Jaspers, J., Shah, P., Ellis, L., Shen, L., Paesante, S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1106 · Cited by 173
Némati, F., Sastre-Garau, X., Laurent, C., Couturier, J., Mariani, P., Desjardins, L., Piperno-Neumann, S., Lantz, O., Asselain, B., Plancher, C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3066 · Cited by 165
Zhang, J., Zhang, L., Su, X., Li, M., Xie, L., Malchers, F., Fan, S., Yin, X., Xu, Y., Liu, K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2694 · Cited by 158
Fichtner, I., Slisow, W., Gill, J. H., Becker, M., Elbe, B., Hillebrand, T., & Bibby, M. (2003) · European Journal of Cancer · doi:10.1016/j.ejca.2003.10.011 · Cited by 156
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer
Serra, V., Eichhorn, P. J. A., García-García, C., Ibrahim, Y. H., Prudkin, L., Sánchez, G., Rodríguez, O., Antón, P., Parra, J.-L., Marlow, S., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66343 · Cited by 154
Lunardi, A., Ala, U., Epping, M. T., Salmena, L., Clohessy, J. G., Webster, K. A., Wang, G., Roberta Mazzucchelli, A., Bianconi, M., Stack, E. C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2650 · Cited by 152
Krumbach, R., Schüler, J. B., Hofmann, M., Giesemann, T., Fiebig, H., & Beckers, T. L. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.12.019 · Cited by 147
Kabos, P., Finlay-Schultz, J., Li, C., Kline, E. C., Finlayson, C. A., Wisell, J. A., Manuel, C. A., Edgerton, S. M., Harrell, J. C., ELIAS, A. D., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2164-8 · Cited by 139
From Human to Mouse and Back: 'Tumorgraft' Models Surge in Popularity
Garber, K. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn481 · Cited by 132
Bankert, R. B., Balu‐Iyer, S. V., Odunsi, K. O., Shultz, L. D., Kelleher, R. J., Barnas, J. L., Simpson-Abelson, M. R., Parsons, R., & Yokota, S. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024420 · Cited by 130
The APL Paradigm and the “Co-Clinical Trial” Project
Nardella, C., Lunardi, A., Patnaik, A., Cantley, L. C., & Pandolfi, P. P. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0061 · Cited by 130
Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer
Gill, R. K., Yang, S.-H., Meerzaman, D. M., Mechanic, L. E., Bowman, E. D., Jeon, H.-S., Roy‐Chowdhuri, S., Shakoori, A., Dracheva, T., Hong, K.-M., et al. (2011) · Oncogene · doi:10.1038/onc.2011.98 · Cited by 126
Moestue, S. A., Borgan, E., Huuse, E. M., Lindholm, E. M., Sitter, B., Børresen‐Dale, A., Engebraaten, O., Mælandsmo, G. M., & Gribbestad, I. S. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-433 · Cited by 122
Laheru, D. A., Shah, P., Rajeshkumar, N. V., McAllister, F. M., Taylor, G., Goldsweig, H. G., Le, D. T., Donehower, R. C., Jimeno, A., Linden, S., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9818-6 · Cited by 104
Ducker, G. S., Atreya, C. E., Simko, J. P., Hom, Y. K., Matli, M. R., Benes, C. H., Hann, B. C., Nakakura, E. K., Bergsland, E. K., Donner, D. B., et al. (2013) · Oncogene · doi:10.1038/onc.2013.92 · Cited by 101
Keysar, S. B., Le, P. N., Anderson, R. T., Morton, J. J., Bowles, D. W., Paylor, J. J., Vogler, B. W., Thorburn, J., Fernandez, P., Glogowska, M. J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4047 · Cited by 97
Walters, D. M., Lindberg, J. M., Adair, S. J., Newhook, T. E., Cowan, C., Stokes, J. B., Borgman, C. A., Stelow, E. B., Lowrey, B. T., Chopivsky, M. E., et al. (2013) · Neoplasia · doi:10.1593/neo.121712 · Cited by 92
Sensitization of Pancreatic Cancer Stem Cells to Gemcitabine by Chk1 Inhibition
Venkatesha, V. A., Parsels, L. A., Parsels, J. D., Zhao, L., Zabludoff, S., Simeone, D. M., Maybaum, J., Lawrence, T. S., & Morgan, M. A. (2012) · Neoplasia · doi:10.1593/neo.12538 · Cited by 91
Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
Garrido‐Laguna, I., Tan, A. C., Uson, M. L., Angenendt, M., W, W., Villaroel, M. C., Zhao, M., Rajeshkumar, N. V., Jimeno, A., Donehower, R. C., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605819 · Cited by 80
Tentler, J. J., Nallapareddy, S., Tan, A. C., Spreafico, A., Pitts, T. M., Morelli, M. P., Selby, H. M., Kachaeva, M. I., Flanigan, S. A., Kulikowski, G. N., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0376 · Cited by 80
Pitter, K. L., Galbán, C. J., Galbán, S., Tehrani, O. S., Li, F., Charles, N. A., Bradbury, M. S., Becher, O. J., Chenevert, T. L., Rehemtulla, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014545 · Cited by 73
Leukemia with distinct phenotypes in transgenic mice expressing PML/RARα, PLZF/RARα or NPM/RARα
Rego, E. M., Ruggero, D., Tribioli, C., Cattoretti, G., Kogan, S. C., Redner, R. L., & Pandolfi, P. P. (2005) · Oncogene · doi:10.1038/sj.onc.1209216 · Cited by 72
Kortmann, U., McAlpine, J. N., Xue, H., Guan, J., Ha, G., Tully, S., Shafait, S., Lau, A., Cranston, A. N., O’Connor, M. J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1382 · Cited by 70
Karam, J. A., Zhang, X.-Y., Tamboli, P., Margulis, V., Wang, H., Abel, E. J., Culp, S. H., & Wood, C. G. (2010) · European Urology · doi:10.1016/j.eururo.2010.11.043 · Cited by 66
Local regulation of human breast xenograft models
Fleming, J. M., Miller, T. C., Meyer, M. J., Ginsburg, E., & Vonderhaar, B. K. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22190 · Cited by 65
Johansson, M., Oudin, A., Tiemann, K., Bernard, A., Golebiewska, A., Keunen, O., Fack, F., Stieber, D., Wang, B., Hedman, H., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not054 · Cited by 63
Hennessey, P. T., Ochs, M. F., Mydlarz, W. W., Hsueh, W. D., Cope, L., Yu, W., & Califano, J. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020584 · Cited by 62
Terziyska, N., Alves, C. C., Groiß, V., Schneider, K., Farkasova, K., Ogris, M., Wagner, E., Ehrhardt, H., Brentjens, R. J., Stadt, U. Z., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052798 · Cited by 59
Drug trials hide conflicts for doctors.
Eichenwald, K., & Kolata, G. B. (1999) · PubMed · Cited by 55
Characterization of the Tumor-Microenvironment in Patient-Derived Cervix Xenografts (OCICx)
Chaudary, N., Pintilie, M., Schwock, J., Dhani, N. C., Clarke, B. A., Milosevic, M., Fyles, A., & Hill, R. P. (2012) · Cancers · doi:10.3390/cancers4030821 · Cited by 54
Short-Term Human Prostate Primary Xenografts
Gray, D. R., Huss, W. J., Yau, J. M., Durham, L. E., Werdin, E. S., Funkhouser, W. K., & Smith, G. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2700 · Cited by 54
Lymphocyte Surface Immunoglobulins in Hodgkin's Disease
Gergely, P., Szegedi, G., Berényi, E., & Petrányi, G. (1973) · New England Journal of Medicine · doi:10.1056/nejm197307262890421 · Cited by 54
Jimeno, A., Rubio‐Viqueira, B., Rajeshkumar, N. V., Chan, A., Solomon, A., & Hidalgo, M. M. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0693 · Cited by 53
de Plater, L., Laugé, A., Guyader, C., Poupon, M. F., Assayag, F., de Crémoux, P., Vincent‐Salomon, A., Stoppa‐Lyonnet, D., Sigal‐Zafrani, B., Fontaine, J.-J., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605900 · Cited by 52
Histological and Molecular Evaluation of Patient-Derived Colorectal Cancer Explants
Uronis, J. M., Osada, T., McCall, S. J., Yang, X. Y., Mantyh, C. R., Morse, M. A., Lyerly, H. K., Clary, B. M., & Hsu, D. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038422 · Cited by 51
Romanelli, A., Clark, A., Assayag, F., Château‐Joubert, S., Poupon, M., Servely, J., Fontaine, J., Liu, X., Spooner, E., Goodstal, S. M., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0441-t · Cited by 46
Wu, X.-H., Zhang, J., Zhen, R., Lv, J., Li, Z., Su, X., Zhu, G., Gavine, P. R., Xu, L., Lu, S., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-180 · Cited by 45
Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting
Nasr, R., & de Thé, H. (2010) · International Journal of Hematology · doi:10.1007/s12185-010-0582-0 · Cited by 43
Raheem, O. A., Kulidjian, A., Wu, C., Jeong, Y. B., Yamaguchi, T., Smith, K. M., Goff, D. J., Leu, H. S., Morris, S., Cacalano, N. A., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-185 · Cited by 42
Fiebig, H., Schüler, J. B., Bausch, N., Hofmann, M., Metz, T. M., & Korrat, A. (2007) · PubMed · Cited by 39
Sanz, L., Cuesta, Á. M., Salas, C., Corbacho, C., Bellas, C., & Álvarez‐Vallina, L. (2008) · Laboratory Investigation · doi:10.1038/labinvest.2008.108 · Cited by 37
Yuen, J. S. P., Sim, M. Y., Siml, H. G., Chong, T. W., Lau, W. K. O., Cheng, C. W.-S., & Huynh, H. T. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.55 · Cited by 33
Jin, K., Li, G., Cui, B., Zhang, J., Lan, H., Han, N., Xie, B., Cao, F., He, K., Wang, H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028384 · Cited by 30
Wong, J., Tang, G., Wu, X., Liang, C., Zhang, Z., Guo, L., Peng, Z., Zhang, W., Lin, X., Wang, Z., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3011838 · Cited by 29
Jin, K., Lan, H., Cao, F., Han, N., Xu, Z., Li, G., He, K., & Teng, L. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1469 · Cited by 25
Restoring invisible and abandoned trials: a call for people to publish the findings
(2013) · BMJ · doi:10.1136/bmj.f4223 · Cited by 14
Jin, K., Lan, H., Cao, F., Xu, Z., Han, N., Li, G., He, K., & Teng, L. (2012) · Oncology Letters · doi:10.3892/ol.2012.603 · Cited by 12
Pitter, K. L., Galbán, C. J., Galbán, S., Tehrani, O. S., Li, F., Charles, N. A., Bradbury, M. S., Becher, O. J., Chenevert, T. L., Rehemtulla, A., et al. (2011) · PLoS ONE · doi:10.1371/annotation/66641ad6-afb9-4d3c-ade6-73fcd5aab061 · Cited by 9
Zhu, H., Zhou, W., Hu, J., Huang, Z., Lao, W., Huang, X., & He, C. (2012) · The Journal of Gene Medicine · doi:10.1002/jgm.2681 · Cited by 6
Challenges to PDTX Models in Drug Development
Eckhardt, S. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt042.48 · Cited by 2
Cited by
Current and future perspectives of liquid biopsies in genomics-driven oncology
Heitzer, E., Haque, I. S., Roberts, C. E. S., & Speicher, M. R. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-018-0071-5 · Cited by 1,557
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D., Böhm, S., Ahmed, A. A., Aspuria, P.-J., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S., Bookman, M. A., et al. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4019 · Cited by 1,367
Imaging biomarker roadmap for cancer studies
O'Connor, J. P. B., Aboagye, E. O., Adams, J. E., Aerts, H. J. W. L., Barrington, S. F., Beer, A. J., Boellaard, R., Bohndiek, S. E., Brady, M., Brown, G., et al. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.162 · Cited by 1,091
Small-cell lung cancer: what we know, what we need to know and the path forward
Gazdar, A. F., Bunn, P. A., & Minna, J. D. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.87 · Cited by 904
Current Challenges and Opportunities in Treating Glioblastoma
Shergalis, A., Bankhead, A., Luesakul, U., Muangsin, N., & Neamati, N. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014944 · Cited by 849
Metadata
- Authors
- Malaney, P., Nicosia, S. V., & Davé, V.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 344
- Issue
- 1
- Pages
- 1-12
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2102624911
- Cited by
- 289
- References
- 93
- FWCI
- 14.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.